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ABSTRACT
Serum procalcitonin (PCT) was measured in 228 children aged 1 month to 15 years at an emergency
department of a hospital located in an area without local malaria transmission in children with sus-
pected infections; 21% (49) children had a clinical syndrome for suspected bacterial infections
(Syndromeþve). In children with Syndromeþve criteria, 27/49 (55.1%) had PCT 0.5mg/l but only
59/179 (32.9%) of those Syndromeve had abnormal PCT, v2¼ 8.0, p¼ 0.005; positive likelihood
ratio¼ 2.0 [95% conﬁdence interval (CI) 1.2–3.3]; negative likelihood ratio¼ 0.8 (95% CI 0.7–1.0).
In patients with pneumonia, 9/15 (60%) with severe pneumonia had PCT 0.5mg/l compared to
11/21 (52.4%) with non-severe pneumonia, v2¼ 0.2, p¼ 0.65. Children with clinical signs of pneu-
monia or clinical signs suggestive of bacterial infections fulﬁlling clinical syndromic deﬁnitions for sus-
pected bacterial infections commonly have elevated PCT level. PCT levels are associated with disease
severity and antibiotic trials guided by PCT levels may be needed where cultures are not available.
KEYWORDS : pneumonia, sepsis, procalcitonin, children, WHO, Africa
INTRODUCTION
Pneumonia and other infections still cause many
deaths in children aged <5 years especially in sub-
Saharan Africa [1]. Clinical criteria consisting of five
clinical syndromes derived from the World Health
Organization (WHO) guidelines have demonstrated
up to 80% sensitivity for identification of children
with invasive bacterial disease in a study in Kilifi,
Kenya, but had low specificity [2–5]. These syn-
dromes include pneumonia, sick young infants (non-
elective admissions aged <60 days old), meningitis/
encephalopathy, severe malnutrition and skin or soft
tissue infection. The study also found the syndromic
criteria mostly missed children with subtle signs of
meningitis, who would be identified from results of
lumbar puncture, but concluded that the criteria is
valuable for identifying children with invasive bacter-
ial disease or at risk of death. The WHO guidelines
recommend antibiotic cover for all cases of child-
hood pneumonia diagnosed using clinical signs, both
severe and non-severe [6], although a recent study
from Pakistan suggests withholding antibiotics in
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non-severe pneumonia cases may be safe [7].
Therefore, questions are emerging whether children
with pneumonia, especially non-severe cases, should all
be treated with antibiotics but findings from Asia may
not be generalizable to Africa because of lower overall
pneumonia case fatality in Asia compared to Africa
[8]. Studies have also shown viruses as important
causes of pneumonia clinically indistinguishable from
that caused by bacteria [9]. A recent study done in
Tanzania also using a criteria derived from WHO guid-
ance [3] showed the syndromic criteria above, with
addition of shock in malaria and clinically defined sep-
sis, had a sensitivity of 60–70% for identification of in-
vasive bacterial disease [4]. These criteria were
developed before introduction of routine infant immu-
nizations for Streptoccous pneumoniae and Haemophilus
influenzae, which have resulted in a decline in inci-
dence of infections from these pathogens [10], and
may no longer be appropriate after the decline.
Therefore, addition of pathogen diagnostics to the
clinical criteria is important for targeted use of antibiot-
ics to meet global desire to reduce antimicrobial resist-
ance. Definitive diagnosis using culture of appropriate
specimens, however, remains a problem and therefore
molecular techniques and various biomarkers may be
used [11] and procalcitonin (PCT) has recently
emerged as a biomarker with good sensitivity, 77%,
and specificity, 79% (area under the receiver operating
characteristic curve 0.85) [12], for early diagnosis of
sepsis [12–14] outside settings where malaria is en-
demic [15]. This study was done in a hospital in
Nairobi, Kenya, an area without local transmission of
malaria, and aimed to investigate whether children
with clinically defined pneumonia or clinical syndromic
criteria derived from WHO guidance, that are used to
target antibiotics prescription in resource poor settings,
have elevated serum PCT, a proxy marker for bacterial
infection. First, changing aetiology of common disease
may indicate increasing non-bacterial causes in chil-
dren with clinical signs previously suggestive of bacter-
ial infection and this study investigates whether
children with syndromic criteria above have possible
bacterial infection, as defined by elevated PCT.
Second, we highlight the validity of PCT test in this
setting and the potential need for specific microbio-
logical diagnosis in children with suspected infections
presenting to emergency settings [16].
METHODS
Study site
The study was conducted at the outpatient department
(OPD) of the Aga Khan University Hospital, a tertiary
care hospital in Nairobi, Kenya. Nairobi is located at an
altitude of 1795m above sea level and has no local
transmission of malaria [17]. Children arriving at the
OPD are first triaged by a nurse, who also measures axil-
lary temperature. Children are then seen by a clinician
on duty who takes a history, counts respiratory and
heart rates, conducts a clinical assessment, and orders
any laboratory or radiological investigations that are
deemed necessary for making diagnosis or patient man-
agement. The clinician also decides whether to admit
the child or whether care can be given as outpatient.
PCT assay is available routinely at the hospital and is
ordered by clinicians when they think it is clinically indi-
cated. The OPD is run by university trained doctors
(medical officers), residents specializing in paediatrics
and newly qualified paediatricians. The study was con-
ducted following scientific and ethical approval from the
Aga Khan University’s Ethics and Research Committee.
Objectives
We primarily aimed to investigate whether children with
clinical diagnosis of pneumonia or with certain clinical
syndromes derived from WHO guidance, which are used
to target antibiotics prescriptions (sick young infants
aged <60days, meningitis/encephalopathy, severe mal-
nutrition and skin or soft tissue infection), have elevated
PCT (0.5mg/l). Children who had pneumonia or any
of these signs were referred to as Syndromeþve and those
without Syndromeve, and are summarized in Table 1
[4, 5]. Meningitis was clinically diagnosed and was not
based on cerebrospinal fluid culture findings.
Study participants
Clinicians at the OPD identified children aged 1 month
to 15 years who had clinical signs suggestive of an infec-
tion, as defined by International Pediatric Sepsis
Consensus Conference (IPSCC) [18], present for 12
or more hours. Illness had to be present for 12 or more
hours because PCT level may not rise in infections
with a duration <12 h. According to IPSCC criteria,
infections are suspected in children with systemic in-
flammatory response syndrome (SIRS), defined as
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abnormal temperature, axillary temperature >38.5C
or <36C, and/or abnormal white blood cell count,
>11 000 cells/ml or <4000 cell/ml, plus either abnor-
mal heart rate (tachycardia-heart rate>140 bpm if aged
>12months and >160 bpm if aged 12months or
bradycardia-heart rate <90 if aged 12months and
<60 bpm if aged >12months) or tachypnoea—
>60 bpm if 12months and >50 bpm if aged
>12months. Because of delays in getting laboratory
results, children were enrolled based on clinical SIRS
criteria. We also modified the fever definition to include
children with history of fever in current illness or those
with abnormal temperature as indicated above.
Children with non-infectious conditions which may
present like SIRS such as trauma, burns or cancer were
excluded. A study nurse stationed at the OPD was then
informed by the clinician about an eligible child. The
study nurse then obtained written informed consent
from parent/care-giver before enrolment into the study.
Participants were consecutively enrolled on weekdays
during working hours.
Sample size
This was a descriptive study conducted over a 4-month
period in 2014 and sample size was not calculated.
Study procedures
A standard medical form was used and clinical informa-
tion was collected prospectively by the attending clinician
at enrolment to enable classification of the participants
into various clinical syndromes used to target antibiotic
prescription as defined in Table 1. Assignment to various
clinical syndromes was done retrospectively from clinical
data entered at assessment. Pneumonia was previously
classified into mild, severe and very severe pneumonia [3,
5] but we have updated the classification into only
two categories, non-severe and severe pneumonia, in line
with updated WHO guidance [2]. A sample for PCT
(0.5ml) was collected during routine sampling or was
separately taken if there were no other tests. The study
paid for costs of PCT assay. Samples were tested
using BRAHMS kit (BRAHMS-Diagnostica GmbH,
Hennigsdorf, Germany) following standard operating
procedures using the Cobas-eV
R
immunoassay analyser. In
this study, we also used other laboratory tests that were
done as part of routine patient care including white cell
count, platelet count, neutrophil count and any culture
results.
Data analysis
We calculated median PCT level and compared the levels
in in various groups using the Kruskal–Wallis test.
Geometric mean PCT levels were also calculated and
compared for various groups. PCT level 0.5mg/l is
regarded as abnormal [19] and proportions with abnor-
mal PCT were calculated and compared using the v2 test.
RESULTS
Participant characteristics
A total of 228 out of 231 participants enrolled between
July and October 2014 had PCT results therefore
Table 1. Deﬁnitions of various clinical syndromes where antibiotics are recommended
Syndrome Definition
Sick young infants Hospitalized children aged <60 days
Meningitis/encephalopathy Neck stiffness, bulging fontanelle or coma
Severe malnutrition Weight for height Z-score <3 or kwashiorkor
Very severe pneumoniaa Lower chest wall indrawing plus one or more of; inability to sit un-
assisted if aged 1 year or inability to drink or breastfeed if aged
<1 year, cyanosis or hypoxia (pulse oximetry <90% in air)
Severe pneumoniab Lower chest wall indrawing
Mild pneumoniab Tachypnoea (50 bpm if aged 60 days to 1 year; 40 bpm if 1-
year old) plus a history of either cough or difﬁculty breathing
Skin or soft tissue infection Cellulitis, abscess and pyomyositis
aNow referred to as severe pneumonia.
bBoth now classiﬁed as non-severe pneumonia.
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results described are based on the 228 participants
with PCT results. Forty-nine children (21.5%) fulfilled
criteria for a clinical syndrome requiring antibiotic
treatment (referred to as Syndromeþve criteria). This
included 36 with pneumonia, 7 with clinically diag-
nosed meningitis/encephalopathy, 3 sick young
infants, 3 with skin or soft tissue infection, and there
was no case of severe malnutrition. The rest of remain-
ing 179 participants were Syndromeve, 146 of whom
had presented with history of cough or difficulty in
breathing but had neither tachypnoea nor chest
indrawing (no pneumonia and Syndromeve) and 33
had none of the syndromes and had no history of
cough or difficulty in breathing. Eight-six children
(37.7%) had PCT level 0.5mg/l. Participants with
Syndromeþve criteria and those Syndromeve were
similar in sex, weight and height—characteristics of
participants are summarized in Table 2. Sixty-two par-
ticipants had blood cultures performed and 57 of these
were negative and the 5 positive cultures were
reported as contaminants. Similarly, 54 participants
had urine cultures done with 47 negative cultures and
the 9 positive urine cultures were reported as contami-
nants. There were no cases of thrombocytopenia.
Cerebrospinal fluid cultures were all negative in five
participants where they were done.
In those with pneumonia, 21 (58.3%) were
non-severe and 15 (41.7%) had severe pneumonia.
A total of 135 children (59.2%) had antibiotics pre-
scribed and 99 (43.2%) participants were admitted.
Thirty-three children with history of travel to the
Coastal or Western Kenya, areas of stable malaria
transmission, who were tested for malaria all had
negative malaria blood smears.
PCT levels in pneumonia and WHO clinical
sepsis syndromes
Overall median (interquartile range) for PCT was 0.27
(0.13–1.38) mg/l and mean6 SD was 3.876 12.6 mg/l
showing non-normal distribution therefore data are
described using median values and geometric means.
Median PCT in those with Syndromeþve criteria was
0.71 (0.18–3.99) mg/l and 0.24 (0.12–0.93) mg/l in
those with Syndromeve criteria, Kruskal–Wallis,
v2¼ 7.5, p¼ 0.006. Median PCT in children with
pneumonia was 0.77 (0.20–5.51) mg/l and in those
without pneumonia (and Syndromeve criteria) was
0.24 (0.12–0.78) mg/l, Kruskal–Wallis, v2¼ 10.0,
p¼ 0.002. Median value in the 13 children with other
Syndromeþve criteria other than pneumonia was 0.61
(0.12–1.61) mg/l.
In children with Syndromeþve criteria, 27/49
(55.1%) had PCT 0.5mg/l but only 59/179
(32.9%) of those Syndromeve had abnormal PCT,
v2¼ 8.0, p¼ 0.005 (Fig. 1). Although presence of
Table 2. Characteristics of participants









Female gender, n (%) 108 (47) 15 (57) 9 (41) 27 (46) 57 (48)
Age in months, median (IQR) 25 (11–42) 37 (18–44) 13 (7–18) 28 (11–42) 22 (13–44)
Weight, mean6 SD 16.16 8.9 17.16 9.7 15.76 11.9 15.56 7.9 16.36 8.6
Height, mean6 SD 1006 23 1046 22 956 30 1006 25 1006 22
Abnormal CRP, n/N (%) 12/18 (67) 4/4 (100) 1/1 (100) 4/5 (80) 3/8 (38)
Leucocytosis, n/N (%) 75/193 (39) 16/26 (62) 7/19 (37) 26/52 (50) 26/96 (27)
Leucopoenia, n/N (%) 5/193 (3) 0/26 (0) 1/19 (5) 0/52 (0) 4/96 (4)
Tachycardia, n (%) 55 (24) 11 (41) 6 (27) 9 (52) 29 (24)
Bradycardia, n (%) 2 (1) 0 (0) 0 (0) 0 (0) 2 (02)
Tachypnoea, n (%) 21 (9) 9 (33) 5 (23) 2 (3) 5 (4)
Admitted, n (%) 99 (43) 22 (81) 15 (68) 25 (42) 37 (31)
CRP, C-reactive protein; IQR, interquartile range.
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Syndromeþve criteria increased the likelihood of hav-
ing PCT 0.5mg/l, positive likelihood ratio¼ 2.0
[95% confidence interval (CI) 1.2–3.3], its absence
(Syndromeve criteria) did not rule out abnormal
PCT, negative likelihood ratio¼ 0.8 (95% CI 0.7–
1.0). In patients with pneumonia, 9/15 (60%) with
severe pneumonia had PCT 0.5mg/l compared to
11/21 (52.4%) with non-severe pneumonia, v2¼ 0.2,
p¼ 0.65. However, PCT 0.5mg/l was present in
47/146 (32.2%) participants presenting with cough or
difficulty in breathing but with no pneumonia (and
Syndromeve criteria), 7/13 (53.9%) of non-
pneumonia cases who were Syndromeþve, and in 12/
33 (36.4%) of participants who were Syndromeve
without cough or difficulty in breathing.
Procalcitonin levels vs. severity of disease
Median PCT in children with severe pneumonia was
1.95 (0.25–45.7) mg/l, geometric mean6 SE
2.726 1.68mg/l, compared to 0.61 (0.18–3.47) mg/l,
geometric mean6 SE 0.706 0.23mg/l, in non-severe
pneumonia (Kruskal–Wallis, v2¼ 2.5, p¼ 0.11)—Figs
2 and 3. When we further examined PCT levels based
on the presence of any number of the following clinical
signs (difficulty in breathing, convulsions, hypoxia,
tachycardia, age <60 days, central cyanosis, chest
indrawing, grunting, acidotic breathing, crackles, weak
pulse volume, capillary refill time >2 s, sunken eyes,
delayed skin pinch, consciousness level is not alert, in-
ability to drink or breastfeed, bulging anterior fonta-
nelle or neck stiffness), geometric means for those with
none of the signs was 0.416 0.08mg/l, one-to-two
signs was 0.426 0.06mg/l, three-to-four signs was
1.206 0.49mg/l and for those with five or more signs
was 2.606 2.20mg/l—Fig. 4. Median PCT level were
significantly higher in participants who were admitted
0.42 (0.13–3.47) mg/l compared to those not admitted
Suspected infecon
(SIRS) with Procalcitonin 
measured 
(N=228)











































1=Syndrome-ve Criteria                     2=Syndrome+ve Criteria
Fig. 2. Geometric mean serum procalcitonin levels
according to sepsis criteria.
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0.24 (0.13–0.74) mg/l, p¼ 0.009, Kruskal–Wallis,
v2¼ 4.4, p¼ 0.04. Children with Syndromeþve criteria
were more likely to be admitted compared to those
without clinical syndromic criteria (Syndromeve), 36/
49 (73.1%) vs. 63/179 (35.2%), odds ratio¼ 5.1 (95%
CI 2.4–10.7) and had higher proportions with PCT
0.5mg/l—27/49 (55%) vs. 59/179 (33%), odds
ratio¼ 2.5 (95% CI 1.3–4.8).
DISCUSSION
We aimed to investigate possible bacterial aetiology




































1=Non-severe Pneumonia                       2=Severe  Pneumonia
Fig. 3. Geometric mean serum procalcitonin in severe and non-severe pneumonia. Note: 1¼mild pneumonia;































1=zero signs; 2=one-two signs; 3=three-four signs; 4=five or more signs
Fig. 4. Geometric mean serum procalcitonin levels in relationship to number of clinical signs.
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with pneumonia and/or syndromic clinical criteria
derived from WHO guidance that are commonly
used to target antibiotic prescription using PCT, a
biomarker with high specificity for bacterial infection.
The study is important because clinical signs alone
poorly target children with infection and may result
in inappropriate use of antibiotics and attendant risk
of antimicrobial resistance [4, 5]. WHO criteria
widely used by clinicians in resource poor settings to
target antibiotic prescriptions were developed before
routine introduction of H. influenzae and pneumo-
coccal vaccines and the signs could be less specific
due to change in microbial aetiology of infections
where viral infections could be more prominent than
previously [5, 10, 20]. We found that children with
pneumonia or other syndromic clinical criteria used
to target antibiotics prescription have higher median
PCT levels compared to those without the syn-
dromes. We also found that PCT has criterion valid-
ity in this population since higher levels were
associated with more severe disease categories.
However, PCT levels though higher in severe pneu-
monia were not significantly different from those in
non-severe pneumonia although this may be due to
the small sample size. The study hospital is in an
area without local transmission of malaria and mal-
aria infection was unlikely in those with elevated
PCT levels.
Several studies have shown usefulness of PCT
measurement and levels for identifying children for
antibiotic prescription, its correlation with severity of
disease, and elevated levels in community acquired
pneumonia and are consistent with our findings [12,
21–27]. The syndromic criteria on their own lack ad-
equate sensitivity as shown from studies in Kenya [5]
and Tanzania [4] and still miss 20–40% of invasive
bacteria disease depending on the underlying context.
It is therefore possible that children without syndrom-
ic criteria who have abnormal PCT levels are those
that are missed by the syndromic criteria but we can-
not say this with certainty since PCT also lacks ad-
equate specificity and is not a replacement for
cultures, the gold standard. Our study is unique be-
cause it broadly describes how these syndromic crite-
ria compares to PCT biomarker in this study setting
where it has not been done previously. The syndromic
criteria are widely used by clinicians in resource poor
countries and this is likely to continue because of lack
of appropriate diagnostics but with shortcomings of
the syndromic criteria and because PCT assay is im-
perfect, it is difficult to interpret abnormal PCT levels.
PCT levels may be useful in monitoring response to
treatment since higher levels are associated with more
severe disease as found in this study and in previous
studies. Use of additional investigations or more clin-
ical signs have been suggested to improve the syn-
dromic criteria [5, 28] but inadequate clinical
assessment at hospitals is common in resource poor
settings [29–31] and this may not solve the problem
and investigations such as lumbar punctures are infre-
quently done [32]. Clinicians in our study had high
level of pre-practice training and were trained in
symptom recognition before the study commenced
and we believe proper clinical assessments were done.
PCT levels are positively correlated with disease se-
verity but since abnormal levels are seen in even in
those without severe disease, this study is unable to rec-
ommend antibiotic prescription by PCT levels only.
However, because accurate microbiological culture
results are unlikely to be widely available soon in re-
source poor settings, clinical trials on antibiotics guided
by PCT levels may be required to assess the place of
PCT for guiding antibiotic prescription. If such trials
prove efficacious then PCT levels could be considered
an empiric criterion for identification of children for
antibiotic treatment. While this would not help in track-
ing antimicrobial resistance, it has potential for improv-
ing antibiotic stewardship. The study hospital is private
fee-charging institution and serves mainly population of
middle-high income earners and this may explain why
severe acute malnutrition, a known risk factor of death
and bacteraemia, was not seen. Our findings are applic-
able to settings without stable high malaria transmission
and this includes many areas in Kenya [17] and Africa
due to the shrinking malaria map and many areas have
zero local transmission [33, 34]. Our study was limited
because we did not have microbial diagnosis and PCT
was only measured once at the time of assessment and
this may miss levels that rise later and serial measure-
ments are recommended [35].
CONCLUSION
In an area without local malaria transmission, raised
serum PCT levels are common in children presenting
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to emergency department with clinical signs of pneu-
monia or fulfilling clinical syndromic definitions for
suspected bacterial infections and there is an associ-
ation between elevated serum PCT levels and disease
severity. Clinical trials of antibiotic therapy based on
PCT assay should be considered in settings where ac-
curate microbiological diagnosis is not available to
fully understand its utility for guiding antibiotic
therapy.
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